A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling

Journal of Immunology

Volumn 191, Issue 6, 2013, Pages 2956-2966

  Fang, Feng ^a   Ooka, Kohtaro ^a   Sun, Xiaoyong ^b   Shah, Ruchi ^a   Bhattacharyya, Swati ^a   Wei, Jun ^a   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA INTERFERON; COLLAGEN; INTERFERON; INTERFERON RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; SMAD7 PROTEIN; TOLL LIKE RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ALPHA SMOOTH MUSCLE ACTIN GENE; ARTICLE; AUTOCRINE EFFECT; COLLAGEN GENE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE GENE; LUNG FIBROBLAST; MALE; PREPUCE; PRIORITY JOURNAL; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN FIBROBLAST; SKIN FIBROSIS;

ADULT; ANIMALS; AUTOCRINE COMMUNICATION; BLOTTING, WESTERN; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTERFERONS; LIGANDS; MICE; MICROSCOPY, CONFOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; TRANSCRIPTOME; TRANSFECTION;

EID: 84884247600     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300376     Document Type: Article

References (50)

1. Jimenez, S. A., and C. T. Derk. 2004. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann. Intern. Med. 140: 37-50.
2. Bhattacharyya, S., J. Wei, and J. Varga. 2011. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat. Rev. Rheumatol. 8: 42-54.
3. Varga, J., and B. Pasche. 2008. Antitransforming growth factor-b therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr. Opin. Rheumatol. 20: 720-728.
4. Sozzani, S., D. Bosisio, M. Scarsi, and A. Tincani. 2010. Type I interferons in systemic autoimmunity. Autoimmunity 43: 196-203.
5. Hall, J. C., and A. Rosen. 2010. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat. Rev. Rheumatol. 6: 40-49.
6. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11: 373-384.
7. Hennessy, E. J., A. E. Parker, and L. A. O'Neill. 2010. Targeting Toll-like receptors: emerging therapeutics? Nat. Rev. Drug Discov. 9: 293-307.
8. Cavassani, K. A., M. Ishii, H. Wen, M. A. Schaller, P. M. Lincoln, N. W. Lukacs, C. M. Hogaboam, and S. L. Kunkel. 2008. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J. Exp. Med. 205: 2609-2621.
9. Kato, H., O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto, K. Matsui, S. Uematsu, A. Jung, T. Kawai, K. J. Ishii, et al. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105.
10. Radstake, T. R., O. Gorlova, B. Rueda, J. E. Martin, B. Z. Alizadeh, R. Palomino-Morales, M. J. Coenen, M. C. Vonk, A. E. Voskuyl, A. J. Schuerwegh, et al; Spanish Scleroderma Group. 2010. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat. Genet. 42: 426-429.
11. Jeong, W. I., O. Park, S. Radaeva, and B. Gao. 2006. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44: 1441-1451.
12. Wild, J. S., D. M. Hyde, and S. N. Giri. 1994. Dose and regimen effects of poly ICLC, an interferon inducer, in a multi-dose bleomycin model of interstitial pulmonary fibrosis. Pharmacol. Toxicol. 75: 42-48.
13. Farina, G. A., M. R. York, M. Di Marzio, C. A. Collins, S. Meller, B. Homey, I. R. Rifkin, A. Marshak-Rothstein, T. R. Radstake, and R. Lafyatis. 2010. Poly(I:C) drives type I IFN-and TGFb-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J. Invest. Dermatol. 130: 2583-2593.
14. Varga, J., D. Brenner, and S. H. Phan. 2005. Fibrosis Research, Methods and Protocols. Humana Press, Totowa, N.J.
15. Stirnweiss, A., A. Ksienzyk, K. Klages, U. Rand, M. Grashoff, H. Hauser, and A. Kröger. 2010. IFN regulatory factor-1 bypasses IFN-mediated antiviral effects through viperin gene induction. J. Immunol. 184: 5179-5185.
16. Fang, F., A. J. Flegler, P. Du, S. Lin, and C. V. Clevenger. 2009. Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. Am. J. Pathol. 174: 297-308.
17. Fang, F., K. Ooka, S. Bhattacharyya, J. Wei, M. Wu, P. Du, S. Lin, F. Del Galdo, C. A. Feghali-Bostwick, and J. Varga. 2011. The early growth response gene Egr2 (alias Krox20) is a novel transcriptional target of transforming growth factor-b that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am. J. Pathol. 178: 2077-2090.
18. Fang, F., G. Antico, J. Zheng, and C. V. Clevenger. 2008. Quantification of PRL/ Stat5 signaling with a novel pGL4-CISH reporter. BMC Biotechnol. 8: 11.
19. Montesano, R., and L. Orci. 1988. Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc. Natl. Acad. Sci. USA 85: 4894-4897.
20. Du, P., W. A. Kibbe, and S. M. Lin. 2008. lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548.
21. Lin, S. M., P. Du, W. Huber, and W. A. Kibbe. 2008. Model-based variancestabilizing transformation for Illumina microarray data. Nucleic Acids Res. 36: e11.
22. Milano, A., S. A. Pendergrass, J. L. Sargent, L. K. George, T. H. McCalmont, M. K. Connolly, and M. L. Whitfield. 2008. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 3: e2696.
23. Dennis, G., Jr., B. T. Sherman, D. A. Hosack, J. Yang, W. Gao, H. C. Lane, and R. A. Lempicki. 2003. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 4: P3.
24. Wong, D., B. Kea, R. Pesich, B. W. Higgs, W. Zhu, P. Brown, Y. Yao, and D. Fiorentino. 2012. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS ONE 7: e29161.
25. Zhao, W., J. Qi, L. Wang, M. Zhang, P. Wang, and C. Gao. 2012. LY294002 inhibits TLR3/4-mediated IFN-b production via inhibition of IRF3 activation with a PI3K-independent mechanism. FEBS Lett. 586: 705-710.
26. Sen, G. C., and S. N. Sarkar. 2005. Transcriptional signaling by double-stranded RNA: role of TLR3. Cytokine Growth Factor Rev. 16: 1-14.
27. Mori, Y., S. J. Chen, and J. Varga. 2000. Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factor-b. Exp. Cell Res. 258: 374-383.
28. Higgs, B. W., Z. Liu, B. White, W. Zhu, W. I. White, C. Morehouse, P. Brohawn, P. A. Kiener, L. Richman, D. Fiorentino, et al. 2011. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 70: 2029-2036.
29. Duan, H., J. Fleming, D. K. Pritchard, L. M. Amon, J. Xue, H. A. Arnett, G. Chen, P. Breen, J. H. Buckner, J. A. Molitor, et al. 2008. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum. 58: 1465-1474.
30. York, M. R., T. Nagai, A. J. Mangini, R. Lemaire, J. M. van Seventer, and R. Lafyatis. 2007. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists. Arthritis Rheum. 56: 1010-1020.
31. Dieudé, P., M. Guedj, J. Wipff, B. Ruiz, E. Hachulla, E. Diot, B. Granel, J. Sibilia, K. Tiev, L. Mouthon, et al. 2009. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 60: 2472-2479.
32. Liu, X., M. D. Mayes, F. K. Tan, M. Wu, J. D. Reveille, B. E. Harper, H. T. Draeger, E. B. Gonzalez, and S. Assassi. 2013. Correlation of interferoninducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum. 65: 226-235.
33. Niimi, K., K. Asano, Y. Shiraishi, T. Nakajima, M. Wakaki, J. Kagyo, T. Takihara, Y. Suzuki, K. Fukunaga, T. Shiomi, et al. 2007. TLR3-mediated synthesis and release of eotaxin-1/CCL11 from human bronchial smooth muscle cells stimulated with double-stranded RNA. J. Immunol. 178: 489-495.
34. Triantafyllopoulou, A., C. W. Franzke, S. V. Seshan, G. Perino, G. D. Kalliolias, M. Ramanujam, N. van Rooijen, A. Davidson, and L. B. Ivashkiv. 2010. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc. Natl. Acad. Sci. USA 107: 3012-3017.
35. Yarilina, A., E. DiCarlo, and L. B. Ivashkiv. 2007. Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J. Immunol. 178: 2204-2211.
36. Ma, B., C. S. Dela Cruz, D. Hartl, M. J. Kang, S. Takyar, R. J. Homer, C. G. Lee, and J. A. Elias. 2011. RIG-like helicase innate immunity inhibits vascular endothelial growth factor tissue responses via a type I IFN-dependent mechanism. Am. J. Respir. Crit. Care Med. 183: 1322-1335.
37. Wild, J. S., D. M. Hyde, H. R. Hubbell, and S. N. Giri. 1996. Dose-related effects of Ampligen (poly(I)•poly(C12U)), a mismatched double-stranded RNA, in a bleomycin-mouse model of pulmonary fibrosis. Exp. Lung Res. 22: 375-391.
38. Hyde, D. M., and S. N. Giri. 1990. Polyinosinic-polycytidylic acid, an interferon inducer, ameliorates bleomycin-induced lung fibrosis in mice. Exp. Lung Res. 16: 533-546.
39. Giri, S. N., and D. M. Hyde. 1988. Ameliorating effect of an interferon inducer polyinosinic-polycytidylic acid on bleomycin-induced lung fibrosis in hamsters. Morphologic and biochemical evidence. Am. J. Pathol. 133: 525-536.
40. Lundberg, A. M., S. K. Drexler, C. Monaco, L. M. Williams, S. M. Sacre, M. Feldmann, and B. M. Foxwell. 2007. Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood 110: 3245-3252.
41. Agarwal, S. K., M. Wu, C. K. Livingston, D. H. Parks, M. D. Mayes, F. C. Arnett, and F. K. Tan. 2011. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res. Ther. 13: R3.
42. Yu, M., and S. J. Levine. 2011. Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to doublestranded RNA viruses. Cytokine Growth Factor Rev. 22: 63-72.
43. Varga, J., A. Olsen, J. Herhal, G. Constantine, J. Rosenbloom, and S. A. Jimenez. 1990. Interferon-g reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-b in normal human fibroblasts. Eur. J. Clin. Invest. 20: 487-493.
44. Freundlich, B., S. A. Jimenez, V. D. Steen, T. A. Medsger, Jr., M. Szkolnicki, and H. S. Jaffe. 1992. Treatment of systemic sclerosis with recombinant interferon-g. A phase I/II clinical trial. Arthritis Rheum. 35: 1134-1142.
45. Yuan, W., T. Yufit, L. Li, Y. Mori, S. J. Chen, and J. Varga. 1999. Negative modulation of alpha1(I) procollagen gene expression in human skin fibroblasts: transcriptional inhibition by interferon-g. J. Cell. Physiol. 179: 97-108.
46. Ghosh, A. K., W. Yuan, Y. Mori, Chen Sj, and J. Varga. 2001. Antagonistic regulation of type I collagen gene expression by interferon-g and transforming growth factor-b. Integration at the level of p300/CBP transcriptional coactivators. J. Biol. Chem. 276: 11041-11048.
47. Ulloa, L., J. Doody, and J. Massagué. 1999. Inhibition of transforming growth factor-b/SMAD signalling by the interferon-g/STAT pathway. Nature 397: 710-713.
48. Bitzer, M., G. von Gersdorff, D. Liang, A. Dominguez-Rosales, A. A. Beg, M. Rojkind, and E. P. Böttinger. 2000. A mechanism of suppression of TGFb/ SMAD signaling by NF-kB/RelA. Genes Dev. 14: 187-197.
49. Seyhan, H., J. Hamzavi, E. Wiercinska, A. M. Gressner, P. R. Mertens, J. Kopp, R. E. Horch, K. Breitkopf, and S. Dooley. 2006. Liver fibrogenesis due to cholestasis is associated with increased Smad7 expression and Smad3 signaling. J. Cell. Mol. Med. 10: 922-932.
50. Chow, E. K., R. M. O'Connell, S. Schilling, X. F. Wang, X. Y. Fu, and G. Cheng. 2005. TLR agonists regulate PDGF-B production and cell proliferation through TGF-b/type I IFN crosstalk. EMBO J. 24: 4071-4081.